What NAD+ is. And why it matters
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in every living cell. It was first described in 1906 by Arthur Harden and William John Young during fermentation research. It is not a peptide, it is a small molecule (~663 Da), but it sits at the center of the longevity conversation and is included here because Peptexa covers the compounds biohackers actually research.
NAD+ participates in over 500 enzymatic reactions. It is essential for converting food to energy (mitochondrial respiration), activating sirtuins (proteins that regulate DNA repair and gene expression), and supporting PARP enzymes (which respond to DNA damage). The critical finding: NAD+ levels decline with age, and this decline correlates with virtually every hallmark of aging.
David Sinclair's lab at Harvard has been the most prominent advocate for NAD+ restoration as an anti-aging strategy, primarily through NMN (Nicotinamide Mononucleotide) supplementation. NR (Nicotinamide Riboside) is another precursor, championed by ChromaDex (TruNiagen).
NAD+ decline with age is one of the most replicated findings in aging biology. The question is not whether NAD+ matters, it clearly does. The question is whether taking a pill to raise NAD+ levels actually reverses aging in humans. That is where the evidence gets thinner.
Mechanism, in plain English
NAD+ sits at the intersection of several critical cellular pathways.
Want all 32 Anti-Aging & Longevity compounds in one place?
The Peptexa Anti-Aging & Longevity guide covers every compound in this category, mechanism, evidence level, and FDA status for each.
What the evidence shows
NAD+ decline with age: Well-established across multiple human and animal studies. NAD+ levels in human tissues decrease significantly with age. This is a replicated finding, not disputed.
NMN supplementation (human data): Multiple human trials show NMN supplementation raises blood NAD+ levels. Some studies report improvements in insulin sensitivity, muscle function, and aerobic capacity in older adults. However, most trials are small, short-duration, and focused on biomarker changes rather than hard aging outcomes.
NR supplementation (human data): Similar to NMN, raises NAD+ levels in human blood. The CHROMADEX-funded trials (NIAGEN) show safety and NAD+ elevation. Functional outcome data is more limited than for NMN.
IV NAD+ (clinical): Administered in wellness and addiction recovery clinics. Limited published clinical trial data. Most evidence is anecdotal or from uncontrolled case series.
Overall evidence level: ★★★☆☆, preliminary human evidence. The biochemistry is sound. NAD+ elevation is achievable. Whether that translates to meaningful anti-aging outcomes in humans is not yet proven by large trials.
The supplement industry has outrun the science. NAD+ precursors are widely sold as anti-aging supplements, but the human clinical evidence supports raising NAD+ levels, not reversing aging. Those are different claims.
Regulatory status
NAD+ precursors (NMN, NR) are marketed as dietary supplements in the United States, not FDA-approved drugs. The FDA briefly attempted to reclassify NMN as a drug ingredient in 2022 but faced legal challenges.
IV NAD+ is administered in clinical settings as a compounded preparation. It is not FDA-approved for any specific indication. Last reviewed 2026-08-19.
Common synonyms researchers use
NAD+ · Nicotinamide Adenine Dinucleotide · NMN (Nicotinamide Mononucleotide, precursor) · NR (Nicotinamide Riboside, precursor) · NAD · NADH (reduced form). Related: TruNiagen (NR brand), various NMN brands.
Safety & adverse-event landscape
NMN and NR have been tested in multiple human supplementation studies and are generally well-tolerated at commonly used amounts. Side effects are described as mild, primarily gastrointestinal (flushing with some niacin-related forms).
IV NAD+ infusions commonly cause chest tightness, nausea, and cramping during administration, these are well-known effects managed by infusion rate adjustment. Long-term safety of chronic NAD+ elevation is not established.
Theoretical concern: NAD+ is required by cancer cells as well as healthy cells. Whether chronic NAD+ elevation affects cancer risk is an open question in the literature.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision involving a peptide or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The full Anti-Aging & Longevity reference
32 compounds. Mechanism, evidence level, and regulatory status for every one.
Get the Anti-Aging & Longevity Guide →